4272 日本化薬

累計 / 通期：4Q / 3Q / 2Q / 1Q

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	241,851	22,454	9.3%	25,478	10.5%	24,641	10.2%	161.18	8.7%	10.1%	14.4%	40.7%
2025/03	4Q	222,584	20,401	9.2%	22,266	10.0%	17,508	7.9%	107.17	10.3%	178.1%	77.2%	325.7%
2024/03	4Q	201,791	7,337	3.6%	12,562	6.2%	4,113	2.0%	24.80	1.7%	-65.9%	-45.4%	-72.6%
2023/03	4Q	198,380	21,505	10.8%	23,025	11.6%	14,984	7.6%	89.36	7.3%	2.2%	-0.6%	-12.8%
2022/03	4Q	184,805	21,050	11.4%	23,154	12.5%	17,181	9.3%	101.70	6.6%	38.5%	40.0%	36.6%
2021/03	4Q	173,381	15,194	8.8%	16,538	9.5%	12,574	7.3%	73.62	-1.0%	-13.1%	-8.3%	-1.9%
2020/03	4Q	175,123	17,485	10.0%	18,026	10.3%	12,815	7.3%	74.25	1.4%	-12.3%	-16.6%	-13.7%
2019/03	4Q	172,639	19,939	11.5%	21,608	12.5%	14,851	8.6%	85.77	-	-	-	-

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	241,851	22,454	9.3%	25,478	10.5%	24,641	10.2%	161.18	8.7%	10.1%	14.4%	40.7%
2025/03	4Q	222,584	20,401	9.2%	22,266	10.0%	17,508	7.9%	107.17	10.3%	178.1%	77.2%	325.7%
2024/03	4Q	201,791	7,337	3.6%	12,562	6.2%	4,113	2.0%	24.80	1.7%	-65.9%	-45.4%	-72.6%
2023/03	4Q	198,380	21,505	10.8%	23,025	11.6%	14,984	7.6%	89.36	7.3%	2.2%	-0.6%	-12.8%
2022/03	4Q	184,805	21,050	11.4%	23,154	12.5%	17,181	9.3%	101.70	6.6%	38.5%	40.0%	36.6%
2021/03	4Q	173,381	15,194	8.8%	16,538	9.5%	12,574	7.3%	73.62	-1.0%	-13.1%	-8.3%	-1.9%
2020/03	4Q	175,123	17,485	10.0%	18,026	10.3%	12,815	7.3%	74.25	1.4%	-12.3%	-16.6%	-13.7%
2019/03	4Q	172,639	19,939	11.5%	21,608	12.5%	14,851	8.6%	85.77	-	-	-	-